M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events

Not Applicable

Recruiting

Conditions: Clinical Stage IV Gastric Cancer AJCC v8
Clinical Stage IVA Gastric Cancer AJCC v8
Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8
Clinical Stage IVB Gastric Cancer AJCC v8
Metastatic Rectal Carcinoma
Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8
Metastatic Gastric Carcinoma
Metastatic Malignant Digestive System Neoplasm
Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8
Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8

Interventions: Other: Best Practice
Other: Questionnaire Administration
Procedure: Patient Monitoring

First Posted Date: 2021-09-09

Last Posted Date: 2025-01-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 750

Registration Number: NCT05038254

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Palliative, Rehabilitation, and Integrated Medicine Handbook for Self Care at Work

Withdrawn

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm

Interventions: Other: Survey Administration

First Posted Date: 2021-09-09

Last Posted Date: 2023-03-31

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05038384

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies

Phase 1

Recruiting

Conditions: Metastatic Malignant Neoplasm in the Liver
Advanced Malignant Solid Neoplasm
Metastatic Malignant Neoplasm in the Lung
Metastatic Malignant Solid Neoplasm

Interventions: Other: Hafnium Oxide-containing Nanoparticles NBTXR3
Radiation: Radiation Therapy

First Posted Date: 2021-09-09

Last Posted Date: 2025-05-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT05039632

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes

Phase 1

Recruiting

Conditions: Chronic Myelomonocytic Leukemia-2
Chronic Myelomonocytic Leukemia-1
Chronic Myelomonocytic Leukemia
Myelodysplastic/Myeloproliferative Neoplasm

Interventions: Drug: Decitabine
Biological: Tagraxofusp-erzs

First Posted Date: 2021-09-09

Last Posted Date: 2025-06-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 64

Registration Number: NCT05038592

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

Phase 2

Terminated

Conditions: Metastatic Cancer
Endometrium Cancer
Endometrial Carcinoma

Interventions: Drug: Pembrolizumab
Drug: Futibatinib

First Posted Date: 2021-09-08

Last Posted Date: 2025-05-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT05036681

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Magnetic Sentinel Lymph Node Mapping in Gastric Cancer

Phase 1

Not yet recruiting

Conditions: Gastric Adenocarcinoma

Interventions: Procedure: Gastrectomy
Drug: Indocyanine Green
Other: Iron Conjugated Polymers in Saline Suspension

First Posted Date: 2021-09-08

Last Posted Date: 2025-03-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT05038098

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients With Minimal Residual Disease

Not Applicable

Recruiting

Conditions: Colorectal Cancer
Colon Cancer

Interventions: Drug: Aspirin
Drug: Vitamin D
Dietary Supplement: Diet
Other: Physical Activity
Behavioral: Behavioral Support Counseling Sessions

First Posted Date: 2021-09-05

Last Posted Date: 2025-02-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 19

Registration Number: NCT05036109

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

Phase 2

Recruiting

Conditions: Breast Cancer
HER2-positive

Interventions: Drug: Zanidatamab
Drug: Letrozole
Drug: Tamoxifen

First Posted Date: 2021-09-05

Last Posted Date: 2025-01-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT05035836

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Contrast-Enhanced Mammography for Breast Cancer Staging in Patients Referred for a Second Opinion

Not Applicable

Completed

Conditions: Breast Carcinoma
Invasive Breast Carcinoma

Interventions: Procedure: Contrast-Enhanced Mammography
Procedure: Digital Tomosynthesis Mammography
Other: Electronic Health Record Review
Drug: Iodinated Contrast Agent

First Posted Date: 2021-09-05

Last Posted Date: 2025-04-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 89

Registration Number: NCT05036083

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Prospective Pilot Study for the Evaluation of 18F- Fluciclovine PET/MRI in Radio-recurrent Prostate Cancer (RRPC-PET/MRI Study)

Not Applicable

Withdrawn

Conditions: Prostate Nodule
Prostate Cancer

Interventions: Radiation: 18F-fluciclovine

First Posted Date: 2021-09-05

Last Posted Date: 2024-01-18

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05035732

Home Terms & Conditions Privacy Policy